DE1492178A1 - Arzneimittel auf Basis von 1,2-alpha-Methylensteroiden und Methode zur Behandlung von Prostataerkrankungen - Google Patents
Arzneimittel auf Basis von 1,2-alpha-Methylensteroiden und Methode zur Behandlung von ProstataerkrankungenInfo
- Publication number
- DE1492178A1 DE1492178A1 DE19651492178 DE1492178A DE1492178A1 DE 1492178 A1 DE1492178 A1 DE 1492178A1 DE 19651492178 DE19651492178 DE 19651492178 DE 1492178 A DE1492178 A DE 1492178A DE 1492178 A1 DE1492178 A1 DE 1492178A1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- acyl radical
- active ingredient
- prostate
- patent department
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title claims description 6
- 208000017497 prostate disease Diseases 0.000 title claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000003098 androgen Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 206010020880 Hypertrophy Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 229940030486 androgens Drugs 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 201000001514 prostate carcinoma Diseases 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 239000013061 administrable dose form Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- -1 1,2a-methylene steroids Chemical class 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229960001712 testosterone propionate Drugs 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KKBWAGPOKIAPAW-UHFFFAOYSA-N butoxyalumane Chemical compound CCCCO[AlH2] KKBWAGPOKIAPAW-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DESC038060 | 1965-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1492178A1 true DE1492178A1 (de) | 1969-12-11 |
Family
ID=7434556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19651492178 Pending DE1492178A1 (de) | 1965-11-22 | 1965-11-22 | Arzneimittel auf Basis von 1,2-alpha-Methylensteroiden und Methode zur Behandlung von Prostataerkrankungen |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE690011A (enrdf_load_stackoverflow) |
| DE (1) | DE1492178A1 (enrdf_load_stackoverflow) |
| FR (1) | FR5985M (enrdf_load_stackoverflow) |
| GB (1) | GB1172086A (enrdf_load_stackoverflow) |
| NL (1) | NL6616424A (enrdf_load_stackoverflow) |
-
1965
- 1965-11-22 DE DE19651492178 patent/DE1492178A1/de active Pending
-
1966
- 1966-11-14 GB GB50901/66A patent/GB1172086A/en not_active Expired
- 1966-11-22 NL NL6616424A patent/NL6616424A/xx unknown
- 1966-11-22 BE BE690011D patent/BE690011A/xx not_active IP Right Cessation
- 1966-11-22 FR FR84433A patent/FR5985M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NL6616424A (enrdf_load_stackoverflow) | 1967-05-23 |
| FR5985M (enrdf_load_stackoverflow) | 1968-04-22 |
| GB1172086A (en) | 1969-11-26 |
| BE690011A (enrdf_load_stackoverflow) | 1967-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69118494T2 (de) | Kontrazeptionsverfahren und Schema | |
| WO1998027929A2 (de) | Therapeutische gestagene zur behandlung von premenstrual dysphoric disorder | |
| DE69901250T2 (de) | 7.alpha.-methyl 19-nortestosteron undecanoat mit androgenischer aktivität | |
| DE3022337A1 (de) | Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen | |
| DE1543273C3 (de) | 7 alpha-Methyl-Delta hoch 5(16) -steroide der Oestranreihe und Verfahren zu deren Herstellung | |
| DE2818586C2 (enrdf_load_stackoverflow) | ||
| DE3687692T2 (de) | Geschlechtshormone zur behandlung von immun-mangel-krankheiten. | |
| DE69330680T2 (de) | Verwendung von 17 Alpha - Dihydroequilenin zur Senkung des Cholesterinspiegels | |
| DE69907495T2 (de) | (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5-(10)-en-20-yn-3-on als reine verbindung | |
| DE69427815T2 (de) | Osteogenese-promoter und mittel gegen osteoporose | |
| DE1492178A1 (de) | Arzneimittel auf Basis von 1,2-alpha-Methylensteroiden und Methode zur Behandlung von Prostataerkrankungen | |
| DE1963317A1 (de) | Chemische Verfahren und Produkte | |
| DE1543474B1 (de) | Zearalenol und Verfahren zu dessen Herstellung | |
| DE2425822A1 (de) | 17 beta-hydroxy-16,16-dimethyloestr-4en-3-on und verfahren zur herstellung desselben | |
| DE2508775C2 (de) | 3-oxo-17β-n-amyloxyöstra-4,9,11-trien, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zusammensetzung | |
| DE2059338C3 (de) | Verwendung von Cyproteronacetat bei der Behandlung der Pubertas praecox | |
| DE3051166C2 (en) | Compsns. for contraception or treatment of gynaecological disorders | |
| EP1753435A1 (de) | Verwendung einer kombination aus ethinylestradiol und chlormadinonacetat zur herstellung eines arzneimittels | |
| DE1593515C3 (de) | 6-Chlor-21 -fluor-1,2alpha-methylen-DeKa hoch 4,6 -pregnadiene, Verfahren zu deren Herstellung sowie diese enthaltende Mittel | |
| DE3129714A1 (de) | Anti-psychotikum | |
| DE1468989C2 (de) | Verfahren zur Herstellung von Gonadienonen, neue Gonadienone und diese enthaltende Mittel | |
| DE2327509A1 (de) | O-(nitroaryl)oxime der 3-ketosteroide | |
| DE1902641C3 (de) | 3-Cyclopentyloxysteroide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| AT241708B (de) | Verfahren zur Herstellung neuer Derivate von 3-Ketosteroiden | |
| DE69323955T2 (de) | Eisentherapie mit Saccharoseoctasulfateisenkomplex |